Shanghai/China. Evonik has received two industry awards for its newly launched short-chain ceramide SPHINOX® Lift and vegetal sourced cholesterol-derivative TEGO® Sterol 7-DHC V. This is the fourth consecutive year that innovations from Evonik have been selected for these awards. In total, 230 entries were submitted by 134 companies to the Ringier Technology Innovation Awards for Personal Care 2022. This double win further strengthens Evonik’s leading position as an innovative specialty chemicals player with strong sustainability principles towards the personal care industry.
“It is a great honour to receive these awards four years in a row! This is a strong testimony to our dedication to create a more sustainable and effective portfolio which is in line with the megatrends of the local skincare industry,” says Madeline Tan, regional business director in Asia North of Evonik’s Care Solutions business line.
As a part of Evonik’s life sciences division Nutrition & Care, the Care Solutions business line is dedicated to developing cutting-edge solutions with superior sustainable attributes and functionality outcomes, and more eco-friendly manufacturing and sourcing processes.
Ceramides by Evonik are considered a flagship solution to enhance, protect and repair the skin and hair’s natural shield. These not only inspire cosmetics formulators, but also enjoy an increasing awareness among end-consumers in China. The portfolio focusing on skin identical ceramides is manufactured based on naturally derived materials as well as advanced natural yeast fermentation processes with less impact on the environment. As one of the latest newcomers to the diverse product family, SPHINOX® Lift tightens the skin and visibly lifts face contours. Due to its bioavailability in deeper skin layers, SPHINOX® Lift functions as a signalling molecule, providing multilayer activity and improving the state of the various skin layers, thus leading to scientifically proven anti-aging and skin-firming efficacy.
TEGO® Sterol 7-DHC V is a 100 percent vegetal-origin, fermentation-based ingredient produced from the oil of pine trees. This new product allows for the same great benefits of traditional 7-DHC, but avoids concerns around sustainability and animal-origin ingredients, such as batch-to-batch variability and potential transmission of diseases or pathogens. A precursor to vitamin D3, TEGO® Sterol 7-DHC V is activated under UV radiation to yield photoprotective benefits for the skin. It has also been found to support skin cell differentiation and promote the production of natural antimicrobial peptides for a healthy skin barrier.
The Ringier Technology Innovation Awards for Personal Care reward innovative products and technologies that contribute to improved production efficiency, cost effectiveness and user convenience. The award is among the most prestigious in China’s beauty industry.
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.38 billion in 2021. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.
Asia Pacific is a strong driving force of the global economy and an important source of innovation. Consequently, Evonik endeavors to further grow its business in the region. Sales reached €3.41 billion in 2021 and the company employs over 5,000 people at more than 50 production sites in Asia Pacific.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.56 billion in 2021 with about 5,300 employees.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.